Of these , 11/37 ( 29.7 % ) in the Fab/Fab cohort experienced late coagulopathy versus 4/39 ( 10.3 % , p < 0.05 ) in the F ( ab ' ) 2/F ( ab ' ) 2 cohort and 2/38 ( 5.3 % , p < 0.05 ) in the F ( ab ' ) 2/placebo cohort .